
Fredun Pharmaceuticals Ltd. (FREDUN) Share Price near 52-week high as stock rises 7.92%
Updated: 8 Oct 2026 • 10:53 am
Posted by:

Fredun Pharmaceuticals Ltd. Share Price is Rs 1,593, up 7.92% from the previous close, and the stock is trading close to its 52-week high as of 08 October 2026 at 10:52 AM IST. The company’s market capitalisation stands at Rs 2,405.33 crore. This Fredun Pharmaceuticals Ltd. Share Price move places FREDUN in the near-peak zone and makes Fredun Pharmaceuticals Ltd. Stock News relevant for readers tracking Fredun Pharmaceuticals Ltd. Share Price Today, Fredun Pharmaceuticals Ltd. Share Price Live and Fredun Pharmaceuticals Ltd. Stock Analysis.
According to latest Univest data, the current reading shows a gap of only Rs 12 from the day’s high and a wider separation from the previous close, which is why the Fredun Pharmaceuticals Ltd. Share Price has drawn attention in the Indian stock market. The latest price event is factual on its own; the data does not establish a company-specific catalyst outside the verified news item that follows. For investors searching Fredun Pharmaceuticals Ltd. Share Price Today or Fredun Pharmaceuticals Ltd. Share Price Update, the main point is simple: the stock is trading close to a 52-week high while also carrying a market cap above Rs 2,400 crore.
Fredun Pharmaceuticals Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,593 |
| Previous Close | Rs 1,476.05 |
| Today's Move | +Rs 116.95 (+7.92%) |
| Open | Rs 1,489.55 |
| High | Rs 1,605 |
| Low | Rs 1,463.45 |
| Market Capitalisation | Rs 2,405.33 crore |
Fredun Pharmaceuticals Ltd. (FREDUN) traded at Rs 1,593 versus the previous close of Rs 1,476.05, a rise of 7.92%. The stock opened at Rs 1,489.55, reached a high of Rs 1,605 and touched a low of Rs 1,463.45.
Fredun Pharmaceuticals Ltd. Share Price opened at Rs 1,489.55, moved between Rs 1,463.45 and Rs 1,605, and was last at Rs 1,593. The stock is up Rs 116.95, or 7.92%, versus the previous close of Rs 1,476.05. That places Fredun Pharmaceuticals Ltd. Share Price close to its 52-week high, with the current level sitting just Rs 12 below the day’s high. The day’s range also shows that the move has extended beyond the opening print and held near the upper end of the range. For readers following Fredun Pharmaceuticals Ltd. Share Price Today and Fredun Pharmaceuticals Ltd. Stock News, this is the key price action fact pattern for the current market update.
Why Fredun Pharmaceuticals Ltd. (FREDUN) May Be Moving Today
According to recent news reports, Fredun Pharmaceuticals is shifting toward a 100% branded healthcare portfolio by 2029, with pet-care investments included in that plan. The company is also expanding capacity and has said it targets doubling revenue and profitability within the next 3 to 4 years. That announcement may be linked to the stock’s near-52-week-high trade, although the latest Univest data only confirms the price event and does not establish the exact cause. For readers scanning Fredun Pharmaceuticals Ltd. Share Price Today, Fredun Pharmaceuticals Ltd. Share News and Fredun Pharmaceuticals Ltd. Latest News, the news flow provides the only verified company-development context attached to today’s move.
Fredun Pharmaceuticals Ltd. (FREDUN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,405.33 crore |
| P/E Ratio | 57.54x |
| P/B Ratio | 8.27x |
| ROE | 16.09% |
| ROCE | 21.34% |
| EPS | Rs 25.65 |
| Book Value Per Share | Rs 178.46 |
| Dividend Yield | 0.02% |
Fredun Pharmaceuticals Ltd. (FREDUN) fundamental metrics show P/E 57.54x, P/B 8.27x, ROE 16.09%, ROCE 21.34%. These figures provide context only and are not a buy or sell signal.
Fredun Pharmaceuticals Ltd. has a market capitalisation of Rs 2,405.33 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 57.54x, P/B at 8.27x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 16.09% and ROCE of 21.34%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 25.65, book value per share of Rs 178.46, dividend yield of 0.02%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 27.91x, median ROE of 11.48%, median ROCE of 13.28%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 57.54x |
| Benchmark Median P/E | 27.91x |
| Benchmark Average P/E | 41.09x |
| Benchmark P/E Range | 0x to 708.87x |
| Company P/B Ratio | 8.27x |
| Benchmark Median P/B | 2.81x |
| Company ROE | 16.09% |
| Benchmark Median ROE | 11.48% |
| Company ROCE | 21.34% |
| Benchmark Median ROCE | 13.28% |
| Company Market Capitalisation | Rs 2,405.33 crore |
| Benchmark Median Market Cap | Rs 828.13 crore |
Fredun Pharmaceuticals Ltd. (FREDUN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 57.54x, which is above the benchmark median of 27.91x, a difference of +106.16%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Fredun Pharmaceuticals Ltd. (FREDUN) has a ROE of 16.09%, which is above the benchmark median of 11.48%, a difference of +40.16%. Fredun Pharmaceuticals Ltd. (FREDUN) has a ROCE of 21.34%, which is above the benchmark median of 13.28%, a difference of +60.69%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,404.27 | 148 | 0.36 | 1.56 | 3.21 |
| Venus Remedies Ltd. | VENUSREM | 2,377.59 | 19.96 | 3.38 | 16.79 | 21.88 |
| Sakar Healthcare Ltd. | SAKAR | 2,332.9 | 62.88 | 6.78 | 6.48 | 8.43 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,322.72 | 139.89 | 2.96 | 4.88 | 6.1 |
| Indoco Remedies Ltd. | INDOCO | 2,287.28 | 403.89 | 2.28 | -10.13 | 0.79 |
Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 57.54x compared with the displayed peer median of 139.89x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 16.09% compares with a peer median of 4.88% across the companies shown in the table. ROCE stood at 21.34% versus the displayed peer median of 6.1%, providing a capital-efficiency comparison. Fredun Pharmaceuticals Ltd. (FREDUN) has a market capitalisation of Rs 2,405.33 crore. Its market capitalisation is larger than each of the 5 peers shown.
About Fredun Pharmaceuticals Ltd.
Fredun Pharmaceuticals Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The latest company update refers to a shift toward a fully branded healthcare portfolio by 2029, with pet-care investments and capacity expansion also part of the stated plan. For readers following Fredun Pharmaceuticals Ltd. Company News and Fredun Pharmaceuticals Ltd. Stock News, that is the core business context available alongside the current market metrics. Univest tracks this company within the Indian stock market so readers can connect Fredun Pharmaceuticals Ltd. Share Price with company background, sector positioning and the latest valuation markers.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
Why is Fredun Pharmaceuticals Ltd. Share Price in the news today?
Ans. Fredun Pharmaceuticals Ltd. Share Price is in focus because it is trading near its 52-week high after rising 7.92% from the previous close. The latest company news also discusses a portfolio shift and expansion plan.
What is Fredun Pharmaceuticals Ltd. Share Price today?
Ans. Fredun Pharmaceuticals Ltd. Share Price is Rs 1,593 as of 08 October 2026 at 10:52 AM IST. It is up Rs 116.95, or 7.92%, from the previous close of Rs 1,476.05.
How close is Fredun Pharmaceuticals Ltd. Share Price to its 52-week high?
Ans. Fredun Pharmaceuticals Ltd. Share Price is trading just Rs 12 below the day’s high of Rs 1,605. That keeps it close to its 52-week high zone and near the top of the current day’s range.
What is Fredun Pharmaceuticals Ltd. market capitalisation?
Ans. Fredun Pharmaceuticals Ltd. has a market capitalisation of Rs 2,405.33 crore. In the same-industry benchmark, that is above the median of Rs 828.13 crore but below the industry average of Rs 14,180.87 crore.
What does Fredun Pharmaceuticals Ltd. Fundamental Analysis show?
Ans. Fredun Pharmaceuticals Ltd. Fundamental Analysis shows P/E of 57.54, P/B of 8.27, ROE of 16.09% and ROCE of 21.34%. EPS is 25.65, book value is 178.46 and dividend yield is 0.02.
How does Fredun Pharmaceuticals Ltd. compare with the healthcare industry?
Ans. Fredun Pharmaceuticals Ltd. Share Price is supported by ROE and ROCE above the same-industry medians, while valuation multiples are also above industry medians. That makes the stock’s pricing and return profile important to compare together.
Which peer is closest to Fredun Pharmaceuticals Ltd. by market cap?
Ans. Among the listed peers, Dishman Carbogen Amcis Ltd. is closest by market cap at Rs 2,404.27 crore. Venus Remedies Ltd. at Rs 2,377.59 crore is also near Fredun Pharmaceuticals Ltd.
Where can I track Fredun Pharmaceuticals Ltd. Share Price Live?
Ans. You can track Fredun Pharmaceuticals Ltd. Share Price Live on Univest, where the stock page brings together price action, valuation ratios, market capitalisation, 52-week levels and company news in one place.
Track Fredun Pharmaceuticals Ltd. Share Price on Univest
Use Fredun Pharmaceuticals Ltd. (FREDUN) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Track Fredun Pharmaceuticals Ltd. Share Price on Univest to follow live levels, company ratios, market capitalisation, 52-week levels and sector context in one place. Univest also helps readers review Fredun Pharmaceuticals Ltd. Stock Analysis, Fredun Pharmaceuticals Ltd. Latest News and Fredun Pharmaceuticals Ltd. Share Price Update without searching across multiple sources.
Recent Articles

Why KPI Green Energy Shares and Waaree Energies Shares Are Rising Today: Prices, the Reported Rs 15,000 Crore Green Ammonia Plan, Q2 and Q1 Numbers, and What Is and Is Not Confirmed
11 November 2026

US AI Sell-Off: Are Indian AI Stocks Next? What Fell on 6 November, Why Nifty IT Rose, How Netweb and E2E Were Hit, and Which Risks and Dates to Watch Before Drawing Conclusions
11 November 2026

Railway Stocks Rally: RVNL and IRFC Jump Up to 10% as Sensex and Nifty Rise, What the Moves Look Like Against a 25% to 32% One-Year Fall, and What Is Not Yet Known
11 November 2026

Ashoka Buildcon Shares Soar 14% After Rs 865.90 Crore NHAI Order: Contract Details, Q2 Loss of Rs 118.96 Crore, Order Book and Debt, and Why the Stock Is Still Down Over a Year
11 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Why KPI Green Energy Shares and Waaree Energies Shares Are Rising Today: Prices, the Reported Rs 15,000 Crore Green Ammonia Plan, Q2 and Q1 Numbers, and What Is and Is Not Confirmed
US AI Sell-Off: Are Indian AI Stocks Next? What Fell on 6 November, Why Nifty IT Rose, How Netweb and E2E Were Hit, and Which Risks and Dates to Watch Before Drawing Conclusions
Railway Stocks Rally: RVNL and IRFC Jump Up to 10% as Sensex and Nifty Rise, What the Moves Look Like Against a 25% to 32% One-Year Fall, and What Is Not Yet Known
Ashoka Buildcon Shares Soar 14% After Rs 865.90 Crore NHAI Order: Contract Details, Q2 Loss of Rs 118.96 Crore, Order Book and Debt, and Why the Stock Is Still Down Over a Year
IndiGo Share Price Jumps 5% as Top Nifty 50 Gainer: Crude Relief, the Q2 Loss, What Brokerages Say on IndiGo Target Price and Upside, and the Risks to Weigh
Popular this week
TD Power Shares Jump 5% as Sensex and Nifty Rally Ahead of Q2 Results on 12 November: The 350% Three-Year Run, the Recent Slide and What the Q1 Base Says

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





